SEC Form 4 · accession 0001104659-16-159830
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — VP, Chief Accounting Officer
Period of report
Nov 29, 2016
Accepted (ET)
Nov 30, 2016 · 7:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $1.58 | Nov 29, 2016 | D | 26,000 | D | — | Jul 1, 2026 | Common Stock | 26,000 | 0 | D |
Explanation of responses
- F125% of the shares of common stock underlying this stock option award were to vest on July 1, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through July 1, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
- F2Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, the option to purchase common stock of the Issuer was exchanged for an option to purchase 26,665 common shares of Novelion Therapeutics Inc. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."